[Skip to Content]
[Skip to Content Landing]
Views 907
Citations 0
News From the Food and Drug Administration
September 1, 2015

New Drug to Lower LDL Cholesterol

JAMA. 2015;314(9):867. doi:10.1001/jama.2015.10491

The first cholesterol-lowering medication in a new class of drugs—proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors—has received FDA approval.

Alirocumab, marketed as Praluent, is approved for use along with diet and statin therapy by adults with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease whose low-density lipoprotein (LDL) cholesterol level is too high (http://1.usa.gov/1CZvYDg).

First Page Preview View Large
First page PDF preview
First page PDF preview